Vircell Showcases Powerful Automation System and Ready-To-Use Diagnostic Kits at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022

Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Image: VIRCLIA LOTUS is based on VIRCLIA monotest technology to process infectious diseases inmunoassays (Photo courtesy of Vircell)

Vircell (Granada, Spain) is participating in this year's edition of MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At MEDICA 2022, Vircell is showcasing its all-in-one CLIA system, VIRCLIA LOTUS which is designed for the automatization of infectious serology with the VirCia Monotest kits. Vircell’s AmpliRun Total Controls are external run controls to monitor the accuracy and precision of the complete analytical process (extraction & amplification). These noninfectious lyophilized run controls include the complete inactivated microorganism in a matrix that mimics human specimens. In combination with the VirClia Monotests, laboratories can daily process a large panel of more than 80 tests with complete traceability. Thanks to the versatility of the VIRCLIA LOTUS fully-automated chemiluminescence solution and wide range of tests for infectious serology, laboratories can process their analysis on a daily basis, without the need to batch samples or refer them to outside centers.

Vircell is also highlighting its VIRPLEX Real Time PCR kits for infectious diseases testing alongside the Aspergillus Galactomannan Ag VIRCLIA Monotest. The test uses sandwich chemiluminescent immunoassay (CLIA) technology for the detection of Aspergillus galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples.

Related Links:
Vircell

Visit expo >

Gold Member

Neonatal Heel Incision Device

Tenderfoot

Online QC Software
Acusera 24•7

Prefilled Tubes

Prefilled 5.0ml Tubes

Food Allergy Screening ELISA Kit

Allerquant 14G B ELISA

Latest MEDICA 2022 News

Channels

Clinical Chemistry

view channel

Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy

Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read more

Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait

Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read more

Blood Protein Panel Predicts Timing of ALS Symptom Onset

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read more

Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Molecular Diagnostics

view channel

Image: Cover artwork featuring the ClairS study (Photo courtesy of Professor Ruibang Luo/HKU)

AI Tool Improves Long-Read Detection of Cancer Mutations

Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more

FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis

Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read more

Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer

Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more

Image Credit: 123RF

Blood Gene Expression Fluctuates More Than Expected Over Time

Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more

Hematology

view channel

Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam

Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more

Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma

Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more

Image: Despite treatment advances, most multiple myeloma patients relapse and identifying high-risk cases at diagnosis remains challenging (Image Credit: Adobe Stock)

New Marker Helps Detect Aggressive Multiple Myeloma Earlier

Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more

Image: A new study shows that an ultrasensitive blood test can detect immune signaling patterns associated with Sjögren’s disease more than a decade before diagnosis (Image Credit: 123RF)

Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis

Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more

New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients

Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more

Microbiology

view channel

New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood

Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more

High-Throughput Automated Platform to Advance Latent Tuberculosis Testing

Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more

Image Credit: Adobe Stock

Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance

Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more

New Rapid Ebola Antigen Test Detects Infection at Point of Care

A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more

Pathology

view channel

AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer

Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more

AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy

Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more

AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer

Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more

Technology

view channel

Training Device Improves Accuracy of Pooled Molecular Diagnostics

High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more

New CE-Certified Software Advances Whole-Genome Cancer Testing

European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more

National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care

Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more

AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines

Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more

Industry

view channel

LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio

LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more

Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD

Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases

NanoSomiX, Inc. and Beckman Coulter Diagnostics announced a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases using extracellular vesicles (EVs).... Read more

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal

Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more